Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 262

Sort by

Sort Order Select

Journal Articles

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Evangelos Terpos, MD PhD, Eftathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Evgenia Verrou, MD, Maria Gavriatopoulou, MD, Alexandros Leonidakis, PhD, Ioannis Ntanasis-Stathopoulos, MD, Sosana Delimpasi, MD, Marie-Christine Kyrtsonis, MD PhD, Maria Papaioannou, Argiris Symeonidis, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1837.

https://doi.org/10.1182/blood-2019-124638

Published: 2019

Journal Articles

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Blood (2019) 134 (Supplement_1): 49.

https://doi.org/10.1182/blood-2019-122374

Published: 2019

Journal Articles

Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma

Kenta Mukaihara, MD PhD, Mattia D'Agostino, MD, Cristina Panaroni, PhD, Keertik Fulzele, PhD, Tomoaki Mori, MD PhD, Ka Tat Siu, PhD, Shrikanta Chattopadhyay, MBBS, Noopur Raje, MD

Blood (2019) 134 (Supplement_1): 4382.

https://doi.org/10.1182/blood-2019-130462

Published: 2019

Journal Articles

Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients

Evangelos Terpos, MD PhD, Nikolaos Kanellias, MD, Eftathios Kastritis, Maria Gavriatopoulou, MD, Vassilis Koutoulidis, MD, Ioannis Ntanasis-Stathopoulos, MD, Aristea-Maria Papanota, MD, Despina Fotiou, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Panagiotis Malandrakis, MD, Tina Bagratuni, PhD, Maria Roussou, MD, Lia A. Moulopoulos, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4326.

https://doi.org/10.1182/blood-2019-123606

Published: 2019

Journal Articles

Outcome of Atypical Presentations of Hairy Cell Leukemia

Afraa Moustafa, MD, Hawraa M Shwaylia, MD, Mahmood Aldapt, MD, Mohamed A Yassin, MBBS, MSc

Blood (2019) 134 (Supplement_1): 5267.

https://doi.org/10.1182/blood-2019-121826

Published: 2019

Journal Articles

Procoagulant Microparticles Derived from Myeloma Plasma Cells Have a Determinant Role in the Hypercoagulable State Associated with Multiple Myeloma. a Modelization in Vitro Study

Loula Papageorgiou, Patrick Van Dreden, PhD, Meletios A. Dimopoulos, MD, Annette Larsen, Mohamad Mohty, MD PhD, Ismail Elalamy, MD PhD, Grigorios T. Gerotziafas

Blood (2019) 134 (Supplement_1): 2425.

https://doi.org/10.1182/blood-2019-124650

Published: 2019

Journal Articles

The Clinical Significance of a Novel microRNA Signature in Multiple Myeloma

Pinelopi I Artemaki, BSc, Aristea-Maria Papanota, MD, Paraskevi Karousi, BSc, Christine Liacos, MSc, Christos K. Kontos, PhD, Dimitris Patseas, BSc, Maria-Alexandra Papadimitriou, BSc, Evangelos Eleutherakis-Papaiakovou, MD, Margaritis Avgeris, PhD, Nikolaos Kanellias, MD, Tina Bagratuni, PhD, Maria Roussou, MD, Ioanna Dialoupi, MD, Eftathios Kastritis, Maria Gavriatopoulou, MD, Meletios A. Dimopoulos, MD, Andreas Scorilas, PhD, Evangelos Terpos, MD PhD

Blood (2019) 134 (Supplement_1): 5529.

https://doi.org/10.1182/blood-2019-129218

Published: 2019

Journal Articles

Treatment with Novel Agents in Patients with Multiple Myeloma in México: Data of Characteristics, Treatment Patterns and Outcomes from a Health Care System

Fernando Pérez-Jacobo, MD, Elia Zamora P., MD, Irma Leticia Barrios-Hernández, MD, Nubia Paloma Pérez-Mar, MD, Lidia Mondragón-Posadas, MD, Patricia Galindo-Delgado, MD, Magdalena Bahena-García, MD, Adrian Hernández-López, MD

Blood (2019) 134 (Supplement_1): 5562.

https://doi.org/10.1182/blood-2019-127582

Published: 2019

Journal Articles

Establishment and Characterization of a Myeloma Cell Line- Aku-MY01

Sheerien Kareem Rajput, BSc,MSc, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA

Blood (2019) 134 (Supplement_1): 5535.

https://doi.org/10.1182/blood-2019-132238

Published: 2019

Journal Articles

Mechanical Loading Shows Anti-Myeloma Effects While Rescuing Bone Loss with Net Bone Formation in a Myeloma Bone Disease Murine Model

Fani Ziouti, Maximilian Rummler, Andreas Brandl, PhD, Andreas Beilhack, MD, Maureen Lynch, PhD, Bettina Willie, PhD, Franziska Jundt, MD

Blood (2018) 132 (Supplement 1): 3164.

https://doi.org/10.1182/blood-2018-99-116796

Published: 2018

Journal Articles

Prospective Evaluation of 18-F FDG PET/CT and Biopsies of Osteolytic Lesions and Random Bone Marrow Samples in Newly Diagnosed Multiple Myeloma Patients

Sandra Sauer, MD, Christos Sachpekidis, Simone Brandelik, Daniel Spira, Stefanie Huhn, Barbara Wagner, Manuela Hummel, Antonia Dimitrakopoulou-Strauss, Jennifer Mosebach, Stefan Delorme, Hartmut Goldschmidt, MD, Carsten Müller-Tidow, MD, Jens Hillengass, MD

Blood (2018) 132 (Supplement 1): 3180.

https://doi.org/10.1182/blood-2018-99-115201

Published: 2018

Journal Articles

Relationship between Bone Marrow PD-1 and PD-L1 Expression and the Presence of Osteolytic Bone Disease in Multiple Myeloma Patients

Federica Costa, MS, Marina Bolzoni, PhD, Rosanna Vescovini, PhD, Fabrizio Accardi, MD, Anna Benedetta Dalla Palma, MD, Federica De Luca, PhD, Valentina Marchica, MS, Denise Toscani, PhD, Emanuela Vicario, MS, Paola Storti, PhD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2018) 132 (Supplement 1): 3183.

https://doi.org/10.1182/blood-2018-99-118200

Published: 2018

Journal Articles

Asian Subgroup Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Chang-Ki Min, MD PhD, Sung-Soo Yoon, MD PhD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS, Shang-Yi Huang, MD, PhD, Cheng-Shyong Chang, MD, Raymond Siu Ming Wong, Kazuyuki Shimizu, MD PhD, Nan Gao, Anthony Glennane, MD, Xuesong Guan

Blood (2018) 132 (Supplement 1): 3251.

https://doi.org/10.1182/blood-2018-99-113132

Published: 2018

Journal Articles

Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Evangelos Terpos, MD PhD, Wolfgang Willenbacher, MD, Kazuyuki Shimizu, MD PhD, Ramon García-Sanz, MD PhD, Anthony Glennane, MD, Xuesong Guan, Daniela Niepel, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 1969.

https://doi.org/10.1182/blood-2018-99-113587

Published: 2018

Journal Articles

Development and Characterisation of an in Vitro Model of Multiple Myeloma

Thomas Lewis, BSc, Elisabeth Jane Walsby, PhD, Stephen Man, Christopher Fegan, Chris Pepper, BSc, PhD

Blood (2018) 132 (Supplement 1): 4505.

https://doi.org/10.1182/blood-2018-99-111842

Published: 2018

Journal Articles

Meta-Analysis Illustrates Role of Interferon-γ Signaling in Multiple Myeloma Pathogenesis

Jihad Aljabban, MMSc, BA, Nabeal Aljabban, BS, Mohamad Mukhtar, BS, Saad Syed, BS, Ross Wanner, BS, Francesca Cottini, MD, Tiffany Hughes, BS, PhD, Kareem Saleh, BS, Evan C Catton, Taylor Gonzalez, Maryam Panahiazar, PhD, Dexter Hadley, MD PhD, Don M. Benson, Jr., MD PhD

Blood (2018) 132 (Supplement 1): 4510.

https://doi.org/10.1182/blood-2018-99-112265

Published: 2018

Journal Articles

Myeloma-Induced Alterations of Glutamine Metabolism Impair Bone Microenvironment Niche in Multiple Myeloma Patients

Denise Toscani, PhD, Martina Chiu, PhD, Giuseppe Taurino, MS, Emanuela Vicario, MS, Valentina Marchica, MS, Fabrizio Accardi, MD, Anna Benedetta Dalla Palma, MD, Paola Storti, PhD, Gaetano Donofrio, PhD, Franco Aversa, MD, Ovidio Bussolati, MD PhD, Nicola Giuliani, MD PhD

Blood (2018) 132 (Supplement 1): 4481.

https://doi.org/10.1182/blood-2018-99-111337

Published: 2018

Journal Articles

Exosomes Play a Key Role in Multiple Myeloma Bone Disease and Tumor Development

Sylvia Faict, MD, Josephine Muller, PhD, Kim De Veirman, PhD, Ken Maes, Elke De Bruyne, PhD, Rik Schots, Jo Caers, MD PhD, Karin Vanderkerken, PhD, Eline Menu, PhD

Blood (2018) 132 (Supplement 1): 4484.

https://doi.org/10.1182/blood-2018-99-112428

Published: 2018

Journal Articles

Concomitant BRAF Mutation in Hairy Cell Leukemia and Papillary Thyroid Cancer

Shehab Mohamed, MD, Mohamed A Yassin, MBBS, MSc, Abdulqadir Jeprel Nashwan, BSN, MSN, RN, CBT-HMS, Halima El Omri, Firyal Ibrahim, MB, CHB, PhD, Susana El akiki, PhD

Blood (2018) 132 (Supplement 1): 5140.

https://doi.org/10.1182/blood-2018-99-116084

Published: 2018

Journal Articles

Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry

Ioannis Tsonis, MD, Nikolaos Kanellias, MD, Vasileios Lazaris, Panayiotis Panayiotidis, MD PhD, Damianos Sotiropoulos, MD, Theodoros Vassilakopoulos, MD, Zoi Arapidou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Dimitrios Boutsis, Athanasios Galanopoulos, MD PhD, Ioannis Kotsianidis, MD PhD, Marie-Christine Kyrtsonis, MD PhD, Theoni Leonidopoulou, MD, Gerasimos Pangalis, MD, Maria Papaioannou, Sophia Polychronopoulou, MD PhD, Charalampos Pontikoglou, MD PhD, Elias Poulakidas, Christos Poziopoulos, MD, Panagiotis Repousis, MD, Maria Topalidou, Kalliopi Vallianatou, Elina Vervessou, MD, Nora-Athina Viniou, Maria Angelopoulou, MD, Ioannis Baltadakis, MD, Maria Dimou, MD PhD, Eleni Gavriilaki, MD, Theodoros Iliakis, MD, Argiris Symeonidis, MD PhD, Sossana Delibasi, MD, Maria Papathanassiou, Theodoros Marinakis, Panagiotis Tsirigotis, MD, Nikolaos Charchalakis, PhD, Evangelos Terpos, MD PhD, Maria Pagoni

Blood (2018) 132 (Supplement 1): 5463.

https://doi.org/10.1182/blood-2018-99-116693

Published: 2018

NARROW

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma

Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients

Outcome of Atypical Presentations of Hairy Cell Leukemia

Procoagulant Microparticles Derived from Myeloma Plasma Cells Have a Determinant Role in the Hypercoagulable State Associated with Multiple Myeloma. a Modelization in Vitro Study

The Clinical Significance of a Novel microRNA Signature in Multiple Myeloma

Treatment with Novel Agents in Patients with Multiple Myeloma in México: Data of Characteristics, Treatment Patterns and Outcomes from a Health Care System

Establishment and Characterization of a Myeloma Cell Line- Aku-MY01

Mechanical Loading Shows Anti-Myeloma Effects While Rescuing Bone Loss with Net Bone Formation in a Myeloma Bone Disease Murine Model

Prospective Evaluation of 18-F FDG PET/CT and Biopsies of Osteolytic Lesions and Random Bone Marrow Samples in Newly Diagnosed Multiple Myeloma Patients

Relationship between Bone Marrow PD-1 and PD-L1 Expression and the Presence of Osteolytic Bone Disease in Multiple Myeloma Patients

Asian Subgroup Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Development and Characterisation of an in Vitro Model of Multiple Myeloma

Meta-Analysis Illustrates Role of Interferon-γ Signaling in Multiple Myeloma Pathogenesis

Myeloma-Induced Alterations of Glutamine Metabolism Impair Bone Microenvironment Niche in Multiple Myeloma Patients

Exosomes Play a Key Role in Multiple Myeloma Bone Disease and Tumor Development

Concomitant BRAF Mutation in Hairy Cell Leukemia and Papillary Thyroid Cancer

Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only